Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | IMCR |
---|---|---|
09:32 ET | 378 | 31.77 |
09:36 ET | 200 | 31.8 |
09:38 ET | 500 | 31.77 |
09:39 ET | 2342 | 31.52 |
09:41 ET | 100 | 31.52 |
09:43 ET | 100 | 31.66 |
09:48 ET | 100 | 31.52 |
09:50 ET | 2417 | 31.52 |
09:52 ET | 100 | 31.605 |
09:54 ET | 600 | 31.67 |
09:56 ET | 650 | 31.53 |
10:03 ET | 1625 | 31.52 |
10:06 ET | 3146 | 31.43 |
10:10 ET | 1639 | 31.4 |
10:15 ET | 242 | 31.2 |
10:24 ET | 1400 | 31.56 |
10:26 ET | 150 | 31.57 |
10:44 ET | 440 | 31.71 |
10:46 ET | 100 | 31.79 |
10:50 ET | 209 | 31.78 |
10:51 ET | 200 | 31.775 |
10:53 ET | 212 | 31.76 |
10:57 ET | 100 | 31.76 |
11:00 ET | 100 | 31.77 |
11:04 ET | 522 | 31.755 |
11:08 ET | 500 | 31.735 |
11:09 ET | 340 | 31.68 |
11:11 ET | 334 | 31.67 |
11:18 ET | 3670 | 31.4 |
11:20 ET | 100 | 31.31 |
11:26 ET | 354 | 31.24 |
11:27 ET | 300 | 31.23 |
11:29 ET | 100 | 31.17 |
11:33 ET | 120 | 31.18 |
11:36 ET | 100 | 31.17 |
11:38 ET | 100 | 31.24 |
11:40 ET | 100 | 31.14 |
11:45 ET | 200 | 31.19 |
11:49 ET | 492 | 31.15 |
11:51 ET | 100 | 31.04 |
11:58 ET | 195 | 31.04 |
12:00 ET | 100 | 31.04 |
12:07 ET | 3240 | 31.14 |
12:16 ET | 100 | 31.16 |
12:21 ET | 847 | 31.19 |
12:23 ET | 200 | 31.11 |
12:25 ET | 900 | 31.24 |
12:27 ET | 100 | 31.15 |
12:41 ET | 100 | 31.13 |
12:43 ET | 300 | 31.135 |
12:45 ET | 200 | 31.115 |
12:52 ET | 829 | 31.02 |
12:54 ET | 1100 | 31.085 |
01:01 ET | 1139 | 31.07 |
01:06 ET | 220 | 31.03 |
01:08 ET | 100 | 31.075 |
01:10 ET | 3128 | 31.02 |
01:12 ET | 100 | 30.975 |
01:17 ET | 400 | 30.89 |
01:19 ET | 100 | 30.89 |
01:21 ET | 4352 | 30.97 |
01:24 ET | 200 | 30.995 |
01:26 ET | 100 | 30.98 |
01:30 ET | 300 | 30.97 |
01:32 ET | 100 | 30.97 |
01:35 ET | 100 | 30.965 |
01:37 ET | 200 | 30.96 |
01:39 ET | 400 | 31 |
01:42 ET | 200 | 30.985 |
01:44 ET | 100 | 31 |
01:46 ET | 865 | 30.91 |
01:48 ET | 100 | 30.905 |
01:50 ET | 100 | 30.835 |
01:55 ET | 200 | 30.86 |
02:02 ET | 100 | 30.79 |
02:04 ET | 100 | 30.79 |
02:08 ET | 600 | 30.83 |
02:09 ET | 100 | 30.87 |
02:11 ET | 414 | 30.865 |
02:15 ET | 208 | 30.96 |
02:18 ET | 200 | 30.95 |
02:22 ET | 300 | 30.95 |
02:24 ET | 600 | 30.885 |
02:29 ET | 300 | 30.8925 |
02:33 ET | 100 | 30.855 |
02:36 ET | 200 | 30.805 |
02:40 ET | 148 | 30.74 |
02:44 ET | 100 | 30.72 |
02:45 ET | 200 | 30.6 |
02:47 ET | 100 | 30.6 |
02:51 ET | 100 | 30.6 |
02:54 ET | 200 | 30.67 |
02:56 ET | 300 | 30.67 |
02:58 ET | 600 | 30.6 |
03:00 ET | 1370 | 30.6 |
03:02 ET | 1302 | 30.6 |
03:03 ET | 300 | 30.72 |
03:05 ET | 800 | 30.615 |
03:07 ET | 297 | 30.67 |
03:09 ET | 201 | 30.74 |
03:12 ET | 500 | 30.73 |
03:16 ET | 1500 | 30.86 |
03:18 ET | 200 | 30.855 |
03:20 ET | 443 | 30.93 |
03:21 ET | 606 | 30.83 |
03:23 ET | 700 | 30.77 |
03:27 ET | 570 | 30.725 |
03:32 ET | 1313 | 30.595 |
03:34 ET | 1425 | 30.76 |
03:36 ET | 3250 | 30.76 |
03:38 ET | 6288 | 31.005 |
03:39 ET | 1100 | 31.0671 |
03:41 ET | 5727 | 30.955 |
03:43 ET | 300 | 30.95 |
03:45 ET | 400 | 30.95 |
03:48 ET | 3149 | 30.93 |
03:50 ET | 100 | 30.9 |
03:52 ET | 1119 | 30.93 |
03:54 ET | 1870 | 30.785 |
03:56 ET | 9154 | 30.88 |
03:57 ET | 1900 | 30.87 |
03:59 ET | 32707 | 30.83 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Immunocore Holdings PLC | 1.6B | -28.8x | --- |
Harrow Inc | 1.6B | -47.4x | --- |
Innoviva Inc | 1.2B | 11.8x | -8.76% |
Evolus Inc | 1.1B | -18.0x | --- |
Ligand Pharmaceuticals Inc | 2.0B | 47.5x | -12.71% |
Ocular Therapeutix Inc | 1.7B | -9.6x | --- |
Immunocore Holdings plc is a United Kingdom-based commercial-stage biotechnology company. The Company is engaged in the development of TCR bispecific immunotherapies, ImmTAX, which immunes mobilizing monoclonal TCRs Against X disease, designed to treat a range of diseases, including cancer, autoimmune and infectious disease. The Company has a clinical-stage pipeline of wholly owned and partnered programs across three different therapeutic areas: oncology, infectious diseases, and autoimmune and inflammation diseases. Its lead product, KIMMTRAK, is a TCR therapeutic for the treatment of patients with unresectable or metastatic uveal melanoma (mUM), in the United States, European Union, Canada, Australia and the United Kingdom. Its pipeline products include IMC-F106C, IMC-F115C, IMC-F119C, IMC-F117C, IMC-F113V, IMC-I109V, IMC-SII8AI, among others. Its clinical programs are being conducted with patients with a range of cancers including melanoma, lung, gastric and others.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $1.6B |
---|---|
Revenue (TTM) | $281.5M |
Shares Outstanding | 50.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.72 |
EPS | $-1.07 |
Book Value | $7.42 |
P/E Ratio | -28.8x |
Price/Sales (TTM) | 5.7 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -21.78% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.